Related references
Note: Only part of the references are listed.New Frontiers in the Prevention, Diagnosis, and Treatment of Alzheimer's Disease
Leonardo Guzman-Martinez et al.
JOURNAL OF ALZHEIMERS DISEASE (2021)
The Cholinergic System, the Adrenergic System and the Neuropathology of Alzheimer's Disease
Rola A. Bekdash
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Donecopride, a Swiss army knife with potential against Alzheimer's disease
Christophe Rochais et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Alzheimer's Disease Pharmacotherapy in Relation to Cholinergic System Involvement
Gabriela Dumitrita Stanciu et al.
BIOMOLECULES (2020)
Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT4 receptors activities for the treatment of Alzheimer's disease
Julien Lalut et al.
SCIENTIFIC REPORTS (2020)
Recent Updates in the Alzheimer's Disease Etiopathology and Possible Treatment Approaches: A Narrative Review of Current Clinical Trials
Elahe Zarini-Gakiye et al.
CURRENT MOLECULAR PHARMACOLOGY (2020)
N-alkylpiperidine carbamates as potential anti-Alzheimer's agents
Urban Kosak et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Multidirectional in vitro and in cellulo studies as a tool for identification of multi-target-directed ligands aiming at symptoms and causes of Alzheimer's disease
Natalia Szalaj et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2020)
2020 Alzheimer's disease facts and figures
[Anonymous]
ALZHEIMERS & DEMENTIA (2020)
Harnessing Polypharmacology with Medicinal Chemistry
Maria Laura Bolognesi
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Serotonergic system, cognition, and BPSD in Alzheimer's disease
Saikat Chakraborty et al.
NEUROSCIENCE LETTERS (2019)
A Novel in vivo Anti-amnesic Agent, Specially Designed to Express Both Acetylcholinesterase (AChE) Inhibitory, Serotonergic Subtype 4 Receptor (5-HT4R) Agonist and Serotonergic Subtype 6 Receptor (5-HT6R) Inverse Agonist Activities, With a Potential Interest Against Alzheimer's Disease
Berenice Hatat et al.
FRONTIERS IN AGING NEUROSCIENCE (2019)
Novel multi target-directed ligands targeting 5-HT4 receptors with in cellulo antioxidant properties as promising leads in Alzheimer's disease
Caroline Lanthier et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Reconsideration of Anticholinesterase Therapeutic Strategies against Alzheimer's Disease
Huan Wang et al.
ACS CHEMICAL NEUROSCIENCE (2019)
Current and emerging therapeutic targets of alzheimer's disease for the design of multi-target directed ligands
Laura Blaikie et al.
MEDCHEMCOMM (2019)
Novel Multitarget-Directed Ligands Aiming at Symptoms and Causes of Alzheimer's Disease
Anna Wieckowska et al.
ACS CHEMICAL NEUROSCIENCE (2018)
The cholinergic system in the pathophysiology and treatment of Alzheimer's disease
Harald Hampel et al.
BRAIN (2018)
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease Three Randomized Clinical Trials
Alireza Atri et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
A perspective on multi-target drug discovery and design for complex diseases
Rona R. Ramsay et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2018)
Serotonin 5-HT6 Receptor Antagonists in Alzheimer's Disease: Therapeutic Rationale and Current Development Status
Hilda Ferrero et al.
CNS DRUGS (2017)
AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models
Alexandre V. Ivachtchenko et al.
CURRENT ALZHEIMER RESEARCH (2017)
Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer's disease
Amanda Calhoun et al.
EXPERT OPINION ON EMERGING DRUGS (2017)
Modulating 5-HT4 and 5-HT6 receptors in Alzheimer's disease treatment
Julien Lalut et al.
FUTURE MEDICINAL CHEMISTRY (2017)
Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer's Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients
Lidia Blanco-Silvente et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2017)
Novel 3-(1,2,3,6-Tetrahydropyridin-4-yI)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity
Adam Bucki et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Polder maps: improving OMIT maps by excluding bulk solvent
Dorothee Liebschner et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2017)
Network Analysis of Drug-target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015
Hui-Heng Lin et al.
SCIENTIFIC REPORTS (2017)
Agonist E-6837 and antagonist SB-271046 of 5-HT6 receptors both reverse the depressive-like effect induced in mice by subchronic ketamine administration
Jose E. Suarez-Santiago et al.
BEHAVIOURAL PHARMACOLOGY (2017)
OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins
Edward Harder et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2016)
Learning performances and vulnerability to amyloid toxicity in the butyrylcholinesterase knockout mouse
Tangui Maurice et al.
BEHAVIOURAL BRAIN RESEARCH (2016)
The amyloid hypothesis of Alzheimer's disease at 25years
Dennis J. Selkoe et al.
EMBO MOLECULAR MEDICINE (2016)
Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT6 receptor antagonists. Design, synthesis and biological evaluation
Anna Wieckowska et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease
Samir Yahiaoui et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Synthesis, Molecular Modelling and Biological Evaluation of Novel Heterodimeric, Multiple Ligands Targeting Cholinesterases and Amyloid Beta
Michalina Hebda et al.
MOLECULES (2016)
The 5-HT6 receptor antagonist idalopirdine potentiates the effects of acetylcholinesterase inhibition on neuronal network oscillations and extracellular acetylcholine levels in the rat dorsal hippocampus
Kjartan F. Herrik et al.
NEUROPHARMACOLOGY (2016)
Development of an in-vivo active reversible butyrylcholinesterase inhibitor
Urban Kosak et al.
SCIENTIFIC REPORTS (2016)
Serotonin: A New Hope in Alzheimer's Disease?
Sylvie Claeysen et al.
ACS CHEMICAL NEUROSCIENCE (2015)
Serotonergic 5-HT6 Receptor Antagonists: Heterocyclic Chemistry and Potential Therapeutic Significance
Alka Bali et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2015)
ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB
James A. Maier et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2015)
The Phyre2 web portal for protein modeling, prediction and analysis
Lawrence A. Kelley et al.
NATURE PROTOCOLS (2015)
BUTYRYLCHOLINESTERASE-KNOCKOUT REDUCES BRAIN DEPOSITION OF FIBRILLAR β-AMYLOID IN AN ALZHEIMER MOUSE MODEL
G. Andrew Reid et al.
NEUROSCIENCE (2015)
Novel Arylsulfonamide Derivatives with 5-HT6/5-HT7 Receptor Antagonism Targeting Behavioral and Psychological Symptoms of Dementia
Marcin Kolaczkowski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial
David Wilkinson et al.
LANCET NEUROLOGY (2014)
Cognitive and Neuropsychiatric Impairments in Alzheimer's Disease: Current Treatment Strategies
Anna Borisovskaya et al.
CURRENT PSYCHIATRY REPORTS (2014)
Ligand-Optimized Homology Models of D1 and D2 Dopamine Receptors: Application for Virtual Screening
Marcin Kolaczkowski et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2013)
BUTYRYLCHOLINESTERASE AND THE CHOLINERGIC SYSTEM
G. A. Reid et al.
NEUROSCIENCE (2013)
Structural Basis for Molecular Recognition at Serotonin Receptors
Chong Wang et al.
SCIENCE (2013)
Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins
H. H. J. Gerets et al.
CELL BIOLOGY AND TOXICOLOGY (2012)
Human butyrylcholinesterase produced in insect cells: huprine-based affinity purification and crystal structure
Xavier Brazzolotto et al.
FEBS JOURNAL (2012)
Butyrylcholinesterase Is Associated With β-Amyloid Plaques in the Transgenic APPSWE/PSEN1dE9 Mouse Model of Alzheimer Disease
Sultan Darvesh et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2012)
Data processing and analysis with the autoPROC toolbox
Clemens Vonrhein et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2011)
5-HT6 receptor and cognition
Xabier Codony et al.
CURRENT OPINION IN PHARMACOLOGY (2011)
XDS
Wolfgang Kabsch
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
Features and development of Coot
P. Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Paul D. Adams et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2010)
Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data
Anna Wesolowska
PHARMACOLOGICAL REPORTS (2010)
Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: Detection of amyloid aggregation in solution
Harry Levine
PROTEIN SCIENCE (2010)
electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation
Nigel W. Moriarty et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2009)
Designing Multiple Ligands - Medicinal Chemistry Strategies and Challenges
Richard Morphy et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
The selective 5-HT6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling not neurogenesis, in the hippocampal of dentate granule cells, but formation of mature Wistar rats
Andrew G. Foley et al.
NEUROPHARMACOLOGY (2008)
An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function
Kevin C. F. Fone
NEUROPHARMACOLOGY (2008)
The butyrylcholinesterase knockout mouse as a model for human butyrylcholinesterase deficiency
Bin Li et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity
Joachim Hartmann et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Multi-target therapeutics: when the whole is greater than the sum of the parts
Grant R. Zimmermann et al.
DRUG DISCOVERY TODAY (2007)
Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes
Richard A. Friesner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Lack of localization of 5-HT6 receptors on cholinergic neurons:: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release
Beatriz Marcos et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2006)
The first potent inhibitor of mammalian group X secreted phospholipase A2:: Elucidation of sites for enhanced binding
Brian P. Smart et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
GROMACS: Fast, flexible, and free
D Van der Spoel et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2005)
5-HT6 receptors:: a novel target for cognitive enhancement
ES Mitchell et al.
PHARMACOLOGY & THERAPEUTICS (2005)
4-(2-Aminoethoxy)-N-(phenylsulfonyl)indoles as novel 5-HT6 receptor ligands
P Zhou et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy
RA Friesner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening
TA Halgren et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Cholinesterase inhibitors: new roles and therapeutic alternatives
E Giacobini
PHARMACOLOGICAL RESEARCH (2004)
Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products
Y Nicolet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: Recent challenges and their implications for novel drug development
AV Terry et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Influence of the 5-HT6 receptor on acetylcholine release in the cortex:: Pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist
C Riemer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Engineering of a monomeric and low-glycosylated form of human butyrylcholinesterase - Expression, purification, characterization and crystallization
F Nachon et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2002)
N-arylsulfonylindole derivatives as serotonin 5-HT6 receptor ligands
MGN Russell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
Characterization of SB-271046:: A potent, selective and orally active 5-HT6 receptor antagonist
C Routledge et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
Share Paper
